Product Images Gemcitabine
View Photos of Packaging, Labels & Appearance
- structural formula gemcitabine - gemcitabine 01
- Figure 1: Kaplan-Meier Curve of Progression Free Survival in Gemcitabine plus Carboplatin versus Carboplatin in Ovarian Cancer (N=356) - gemcitabine 02
- Figure 2 - gemcitabine 03
- Figure 3 - gemcitabine 04
- Figure 4 - gemcitabine 05
- Hospira logo - gemcitabine 06
- PRINCIPAL DISPLAY PANEL - 200 mg Vial Label - gemcitabine 07
- PRINCIPAL DISPLAY PANEL - 200 mg Vial Carton - gemcitabine 08
- PRINCIPAL DISPLAY PANEL - 1 g Vial Label - gemcitabine 09
- PRINCIPAL DISPLAY PANEL - 1 g Vial Carton - gemcitabine 10
Product Label Images
The following 10 images provide visual information about the product associated with Gemcitabine NDC 0409-0185 by Hospira, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1: Kaplan-Meier Curve of Progression Free Survival in Gemcitabine plus Carboplatin versus Carboplatin in Ovarian Cancer (N=356) - gemcitabine 02

Figure 2 - gemcitabine 03

The text is describing the results of a study or experiment that involved the drug Paclitaxel. The Log rank p-value is reported as 0.0001, which indicates statistical significance. The third line mentions something about "Time to Documented Disease Progression (Months)", but without further context it is difficult to determine what it means.*
Figure 3 - gemcitabine 04

This text contains statistical data related to the median survival time and survival probability for Gemcitabine/Cisplatin and Cisplatin, as well as statistical tests such as Logrank and Wilcoxon. However, it is not clear what type of study or research this data is from, as there is no additional context.*
Figure 4 - gemcitabine 05

This appears to be a graph displaying the "Fraction Surviving" over "Survival Time (months)" for a treatment named "Gemcitabine". The graph shows data points and a line representing the survival rate of individuals receiving Gemcitabine over the course of treatment. The graph is numbered by months and fractions, with the line starting at 0.8 at 10 months and decreasing to around 0.2 at 20 months.*
PRINCIPAL DISPLAY PANEL - 200 mg Vial Carton - gemcitabine 08

This is a product description of a drug called Gemcitabine, which is a Cytotoxic Agent. It comes in a single-dose vial containing 200mg Gemcitabine for Intravenous use only. The drug also contains 200mg Mannitol, and 125mg Sodium Acetate. The drug is reconstituted by adding 5 mL of 0.9% Sodium Chloride Injection to make a solution containing 38mg/mL. The solution should be administered within 24 hours and should be discarded if unused. The provided text also contains storage and usage instructions.*
PRINCIPAL DISPLAY PANEL - 1 g Vial Carton - gemcitabine 10

Gemcitabine for Injection, USP is a cytotoxic agent that comes in a single-dose vial. Each 1 g vial contains 1 g gemcitabine, 1 g mannitol, and 625 mg sodium acetate. It is recommended to check the package insert for complete product information. To reconstitute, add 25 L of 0.9% Sodium Chloride Injection and shake to dissolve. The solution should be administered within 24 hours and any unused portion should be discarded. The storage temperature before and after reconstitution should be between 20 - 25°C. Gemcitabine Hydrochloride is potentially cytotoxic, so be cautious when handling it.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.